

Detailed Explanation of Bio Analytical Methods for Assessing Environmental Risk

Dr. Michel Brusson*

Department of Biomedical Sciences, Institute of MGR, Chennai, India


Abstract

Environmental risk assessment is a critical process for evaluating the potential impacts of contaminants on ecosystems and human health. Bioanalytical techniques play a vital role in this assessment by measuring the biological responses or biomarkers indicative of exposure, effect, or susceptibility to environmental pollutants. This abstract provides an overview of the bio analytical techniques commonly used in environmental risk assessment. Biomarker analysis involves the measurement of specific biomolecules or biological indicators to assess the presence and impact of contaminants. Nontoxicity testing evaluates the potential of contaminants to cause genetic damage through assays such as the Ames test or comet assay. Enzyme activity assays measure the changes in enzyme function caused by exposure to contaminants, providing insights into metabolic disruption. Immunotoxicity assays assess the adverse effects of contaminants on the immune system, evaluating immune cell function, cytokine production, and the understanding of the risks posed by environmental contaminants. They aid in decision-making processes related to environmental management and regulatory actions, enabling the protection of ecosystems and human health.

*Corresponding author: Dr. Michel Brusson, Department of Biomedical Sciences, Institute of MGR, Chennai, India, E-mail: russon@gmail.com

Received: 01-May-2023, Manuscript No: jabt-23-99300, **Editor assigned:** 03-May-2023, Pre QC No: jabt-23-99300(PQ), **Reviewed:** 17-May-2023, QC No: jabt-23-99300, **Revised:** 19-May-2023, Manuscript No: jabt-23-99300(R), **Published:** 26-May-2023, DOI: 10.4172/2155-9872.1000524

Citation: Brusson M (2023) Detailed Explanation of Bio Analytical Methods for Assessing Environmental Risk



References

1. Hadi MA, José Closs S (2016) Ensuring rigour and trustworthiness of qualitative research in clinical pharmacy. *Int J Clin Pharm* 38:641-646.
2. Al Raiisi F, Stewart D, Fernandez-Llimos F, Salgado TM, Mohamed MF, et al. (2019) Clinical pharmacy practice in the care of chronic kidney disease patients: a systematic review. *Int J Clin Pharm* 41:630-666.
3. Jebara T, Cunningham S, MacLure K, Awaisu A, Pallivalapila A, et al. (2021) Health-related stakeholders' perceptions of clinical pharmacy services in qatar. *Int J Clin Pharm* 43:107-117.
4. Trinh HT, Nguyen HT, Pham VT, Ba HL, Dong PT, et al. (2018) Hospital clinical pharmacy services in vietnam. *Int J Clin Pharm* 40:1144-1153.
5. Lopes H, Lopes AR, Farinha H, Martins AP (2021) Defning clinical pharmacy and support activities indicators for hospital practice using a combined nominal and focus group technique. *Int J Clin Pharm* 1-23.
6. Rotta I, Salgado TM, Silva ML, Correr CJ, Fernandez-Llimos F, et al. (2015) Effectiveness of clinical pharmacy services: an overview of systematic reviews (2000–2010). *Int J Clin Pharm* 37:687-697.
7. Le Corre PA (2019) Prescriptome analytics: an opportunity for clinical pharmacy. *Int J Clin Pharm*, 41:1394-1397.
8. Nguyen JT, Ziser KE, Penm J, Schneider CR (2019) Impact of a pharmacy technician on clinical pharmacy services in an australian hospital. *Int J Clin Pharm* 41:445-451.
9. Deibl S, Mueller D, Kirchdorfer K, Stemer G, Hoppel M, et al. (2020) Self-reported clinical pharmacy service provision in austria: an analysis of both the community and hospital pharmacy sector-a national study. *Int J Clin Pharm* 42:1050-1060.
10. Chen TF, Hughes CM (2016) Why have a special issue on methods used in clinical pharmacy practice research? *Int J Clin Pharm* 38:599-600.